Clinical Trial

Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults

Not Yet Recruiting Phase 1/2

Record status

This record was last updated December 6, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Summary

This is a single centre, randomized, placebo-controlled phase 1/2 study comparing two malaria vaccine candidates. The first vaccine candidate PfSPZ-CVac (Plasmodium falciparum sporozoites (PfSPZ) challenge administered with a chemoprophylactic antimalarial) will be chemoattenuated in vivo with the antimalarial Pyramax. The second vaccine candidate is prime- target vaccination with viral vectored vaccine candidate regime MVA ME-TRAP (Modified Vaccinia Ankara (MVA) multiple epitope thrombosponin-related adhesion protein (ME-TRAP)) and ChAd63 ME-TRAP (Chimpanzee adenovirus 63 (ChAd63). The safety and protective efficacy of both vaccine candidates will be to assessed by controlled human malaria infection with PfSPZ Challenge strain NF54 administered intravenously by syringe.

Protocol Amendment History 4 amendments

This ClinicalTrials.gov record has been amended 4 times since 2022-06-27; most recent amendment 2024-12-03.

Trial Details

NCT Number	NCT05441410
Lead Sponsor	University Hospital Tuebingen Collaborators: Sanaria Inc., University of Oxford
Conditions	Malaria
Enrollment	30 participants
Start Date	2025-06-01
Primary Completion	2026-06-30 (estimated)
Study Completion	2026-06-30 (estimated)
Updated on ClinicalTrials.gov	2024-12-06